Last reviewed · How we verify
Centre for Human Drug Research, Netherlands — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Erythromycin 4% topical gel formulation | Erythromycin 4% topical gel formulation | marketed | ||||
| Clindamycin 1% topical lotion formulation | Clindamycin 1% topical lotion formulation | marketed |
Therapeutic area mix
- Immunology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Abbott · 1 shared drug class
- Altuğ Güner · 1 shared drug class
- Alvotech Swiss AG · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- Assistance Publique Hopitaux De Marseille · 1 shared drug class
- Bio-Thera Solutions · 1 shared drug class
- ASIS Corporation · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centre for Human Drug Research, Netherlands:
- Centre for Human Drug Research, Netherlands pipeline updates — RSS
- Centre for Human Drug Research, Netherlands pipeline updates — Atom
- Centre for Human Drug Research, Netherlands pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centre for Human Drug Research, Netherlands — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-for-human-drug-research-netherlands. Accessed 2026-05-17.